Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry

International Journal of Cardiology

Volumn 223, Issue , 2016, Pages 543-547

  Oh, Seil ^a   Goto, Shinya ^b   Accetta, Gabriele ^c   Angchaisuksiri, Pantep ^d   Camm, A John ^e   Cools, Frank ^f   Haas, Sylvia ^g   Kayani, Gloria ^c   Koretsune, Yukihiro ^h   Lim, Toon Wei ⁱ   Misselwitz, Frank ^j   van Eickels, Martin ^j   Kakkar, Ajay K ^c,k  

^a Seoul National University Hospital   (South Korea)

^b TOKAI UNIVERSITY   (Japan)

^c THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^d MAHIDOL UNIVERSITY   (Thailand)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f Algemeen Ziekenhuis Klina   (Belgium)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h OSAKA NATIONAL HOSPITAL   (Japan)

ⁱ NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^j BAYER PHARMA AG   (Germany)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Atrial fibrillation; International normalized ratio; Vitamin K antagonist

Indexed keywords

ANTIVITAMIN K; ANTICOAGULANT AGENT; VITAMIN K GROUP;

AGED; ARGENTINA; ARTICLE; ATRIAL FIBRILLATION; AUSTRALIA; AUSTRIA; BELGIUM; BRAZIL; CANADA; CHILE; CHINA; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE STUDY; CZECH REPUBLIC; DENMARK; FEMALE; FINLAND; FOLLOW UP; FRANCE; GEOGRAPHIC DISTRIBUTION; GERMANY; HUMAN; HUNGARY; INDIA; INTERNATIONAL NORMALIZED RATIO; ITALY; JAPAN; KOREA; MAJOR CLINICAL STUDY; MALE; MEXICO; NETHERLANDS; NORWAY; OBSERVATIONAL STUDY; POLAND; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RUSSIAN FEDERATION; SINGAPORE; SOUTH AFRICA; SPAIN; SWEDEN; THAILAND; TREND STUDY; UKRAINE; UNITED KINGDOM; ANTAGONISTS AND INHIBITORS; ASIA; BLOOD; CLINICAL TRIAL; GLOBAL HEALTH; INTERNATIONAL COOPERATION; MIDDLE AGED; MULTICENTER STUDY; REGISTER; STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASIA; ATRIAL FIBRILLATION; DATA INTERPRETATION, STATISTICAL; FEMALE; GLOBAL HEALTH; HUMANS; INTERNATIONAL NORMALIZED RATIO; INTERNATIONALITY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; VITAMIN K;

EID: 84982299834     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.08.236     Document Type: Article

References (26)

1. [1] Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med., 154, 1994, 1449–1457.
2. [2] Connolly, S.J., Pogue, J., Eikelboom, J., Flaker, G., Commerford, P., Franzosi, M.G., et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118 (2008), 2029–2037.
3. [3] Camm, A.J., Lip, G.Y., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S.H., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Europace 14 (2012), 1385–1413.
4. [4] January, C.T., Wann, L.S., Alpert, J.S., Calkins, H., Cigarroa, J.E., Cleveland, J.C. Jr., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130 (2014), e199–e267.
5. [5] Ogawa, S., Aonuma, K., Tse, H.-F., Huang, D., Huang, J.-L., Kalman, J., et al. The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. J. Arrhythm. 29 (2013), 190–200.
6. [6] J. C. S. Joint Working Group, Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ. J. 78 (2014), 1997–2021.
7. [7] Kakkar, A.K., Mueller, I., Bassand, J.P., Fitzmaurice, D.A., Goldhaber, S.Z., Goto, S., et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am. Heart J., 2012, 13–19 e1.
8. [8] Composition of Macro Geographical (Continental) Regions, Geographical Sub-regions, and Selected Economic and Other Groupings. 2013, United Nations.
9. [9] Goto, S., Zhu, J., Liu, L., Oh, B.H., Wojdyla, D.M., Aylward, P., et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am. Heart J. 168 (2014), 303–309.
10. [10] Hori, M., Connolly, S.J., Zhu, J., Liu, L.S., Lau, C.P., Pais, P., et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 44 (2013), 1891–1896.
11. [11] Albertsen, I.E., Rasmussen, L.H., Overvad, T.F., Graungaard, T., Larsen, T.B., Lip, G.Y., Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke 44 (2013), 1329–1336.
12. [12] Goto, S., Hankey, G., True Hills, M., Hu, D., Hu, H.H., Lip, G.Y.H., et al. How can we avoid a stroke crisis in the Asia-Pacific region?. Working Group Report: Stroke Prevention in Patients With Atrial Fibrillation, 2011.
13. [13] Inoue, H., Okumura, K., Atarashi, H., Yamashita, T., Origasa, H., Kumagai, N., et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. Circ. J. 77 (2013), 2264–2270.
14. [14] Jun, Z.J., Ping, T., Lei, Y., Li, L., Ming, S.Y., Jing, W., Prevalence of factor V Leiden and prothrombin G20210A mutations in Chinese patients with deep venous thrombosis and pulmonary embolism. Clin. Lab. Haematol. 28 (2006), 111–116.
15. [15] Ro, A., Hara, M., Takada, A., The factor V Leiden mutation and the prothrombin G20210A mutation was not found in Japanese patients with pulmonary thromboembolism. Thromb. Haemost., 82, 1999, 1769.
16. [16] Ozawa, T., Niiya, K., Sakuragawa, N., Absence of factor V Leiden in the Japanese. Thromb. Res. 81 (1996), 595–596.
17. 2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry. Circ. J. 78 (2014), 1593–1599.
18. [18] Singer, D.E., Hellkamp, A.S., Piccini, J.P., Mahaffey, K.W., Lokhnygina, Y., Pan, G., et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J. Am. Heart Assoc., 2013, e000067.
19. [19] Goto, S., Ikeda, Y., Chan, J.C.N., Wilson, P.W.F., Cheng Yeo, T., Liau, C.S., et al. Risk-factor profile, drug usage and cardiovascular events within a year in patients with and a high risk of atherothrombosis recruited from Asia as compared with those recruited from non-Asia regions: a substudy of the REduction of Atherothrombosis for Continued Health (REACH) registry. Heart Asia. 3 (2011), 93–98.
20. [20] Shen, A.Y., Yao, J.F., Brar, S.S., Jorgensen, M.B., Chen, W., Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J. Am. Coll. Cardiol. 50 (2007), 309–315.
21. [21] Yuen, E., Gueorguieva, I., Wise, S., Soon, D., Aarons, L., Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. J. Pharmacokinet. Pharmacodyn. 37 (2010), 3–24.
22. [22] Zhao, F., Loke, C., Rankin, S.C., Guo, J.Y., Lee, H.S., Wu, T.S., et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther. 76 (2004), 210–219.
23. [23] Ueda, K., Hasuo, Y., Kiyohara, Y., Wada, J., Kawano, H., Kato, I., et al. Intracerebral hemorrhage in a Japanese community, Hisayama: incidence, changing pattern during long-term follow-up, and related factors. Stroke 19 (1988), 48–52.
24. [24] Malinowski, H.J., Westelinck, A., Sato, J., Ong, T., Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan. J. Clin. Pharmacol. 48 (2008), 900–908.
25. [25] Levine, G.N., Jeong, Y.H., Goto, S., Anderson, J.L., Huo, Y., Mega, J.L., et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat. Rev. Cardiol. 11 (2014), 597–606.
26. [26] Hori, M., Matsumoto, M., Tanahashi, N., Momomura, S., Uchiyama, S., Goto, S., et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation — the J-ROCKET AF study. Circ. J. 76 (2012), 2104–2111.